Literature DB >> 25771228

Soluble urokinase plasminogen activator receptor as a prognostic marker of all-cause and cardiovascular mortality in a black population.

Shani Botha1, Carla M T Fourie2, Rudolph Schutte3, Jesper Eugen-Olsen4, Ronel Pretorius5, Aletta E Schutte3.   

Abstract

BACKGROUND: Elevated inflammatory markers such as C-reactive protein (CRP) and interleukin-6 (IL-6) are well-known risk factors for cardiovascular mortality. The less familiar marker, soluble urokinase plasminogen activator receptor (suPAR), is known to predict cancer, infections and all-cause mortality. We determined whether suPAR, CRP and IL-6 are predictive of both all-cause and cardiovascular mortality in a black population, highly burdened by cardiovascular disease and HIV infection.
METHODS: We included 1425 black South Africans, of which 208 died within five years after baseline data collection. EDTA plasma biomarker levels were determined, while all-cause and cardiovascular mortality were used as endpoints.
RESULTS: At baseline suPAR, CRP and IL-6 were higher in non-survivors than in survivors (P<0.001). SuPAR (HR 1.27, 95% CI 1.09-1.48), IL-6 (HR 1.49, 95% CI 1.24-1.78) and CRP (HR 1.39, 95% CI 1.17-1.65) predicted all-cause mortality, while only suPAR (HR 1.40, 95% CI 1.04-1.87) and IL-6 (HR 1.61, 95% CI 1.10-2.35) predicted cardiovascular mortality. The prognostic value of suPAR was independent of IL-6 and CRP (P≤0.015).
CONCLUSION: SuPAR predicted both all-cause and cardiovascular mortality, independent of traditional risk factors, HIV and other inflammatory markers, underlining the prognostic value of suPAR in a black population.
Copyright © 2015 Elsevier Ireland Ltd. All rights reserved.

Entities:  

Keywords:  C-reactive protein; Death; Inflammation; Interleukin-6; Predict; South Africa

Mesh:

Substances:

Year:  2015        PMID: 25771228     DOI: 10.1016/j.ijcard.2015.03.041

Source DB:  PubMed          Journal:  Int J Cardiol        ISSN: 0167-5273            Impact factor:   4.164


  21 in total

1.  Soluble Urokinase Plasminogen Activator Receptor and Decline in Kidney Function in Autosomal Dominant Polycystic Kidney Disease.

Authors:  Salim S Hayek; Douglas P Landsittel; Changli Wei; Martin Zeier; Alan S L Yu; Vicente E Torres; Sharin Roth; Christina S Pao; Jochen Reiser
Journal:  J Am Soc Nephrol       Date:  2019-06-06       Impact factor: 10.121

Review 2.  Focal segmental glomerular sclerosis: do not overlook the role of immune response.

Authors:  Francesco Reggiani; Claudio Ponticelli
Journal:  J Nephrol       Date:  2016-02-20       Impact factor: 3.902

Review 3.  Recent advances in understanding hypertension development in sub-Saharan Africa.

Authors:  A E Schutte; S Botha; C M T Fourie; L F Gafane-Matemane; R Kruger; L Lammertyn; L Malan; C M C Mels; R Schutte; W Smith; J M van Rooyen; L J Ware; H W Huisman
Journal:  J Hum Hypertens       Date:  2017-03-23       Impact factor: 3.012

4.  Soluble Urokinase Plasminogen Activator Receptor and Outcomes in Patients with Diabetes on Hemodialysis.

Authors:  Christiane Drechsler; Salim S Hayek; Changli Wei; Sanja Sever; Bernd Genser; Vera Krane; Andreas Meinitzer; Winfried März; Christoph Wanner; Jochen Reiser
Journal:  Clin J Am Soc Nephrol       Date:  2017-05-11       Impact factor: 8.237

5.  Soluble Urokinase Plasminogen Activator Receptor: Genetic Variation and Cardiovascular Disease Risk in Black Adults.

Authors:  Nels C Olson; Laura M Raffield; Anne H Moxley; Tyne W Miller-Fleming; Paul L Auer; Nora Franceschini; Debby Ngo; Timothy A Thornton; Ethan M Lange; Yun Li; Deborah A Nickerson; Neil A Zakai; Robert E Gerszten; Nancy J Cox; Adolfo Correa; Karen L Mohlke; Alexander P Reiner
Journal:  Circ Genom Precis Med       Date:  2021-10-28

6.  Soluble Urokinase-type Plasminogen Activator Receptor Predicts All-cause 5-Year Mortality in Ischemic Stroke and TIA.

Authors:  Juha Onatsu; Mikko Taina; Pirjo Mustonen; Marja Hedman; Antti Muuronen; Otso Arponen; Miika Korhonen; Pekka Jäkälä; Ritva Vanninen; Kari Pulkki
Journal:  In Vivo       Date:  2017 May-Jun       Impact factor: 2.155

7.  Soluble Urokinase-Type Plasminogen Activator Receptor in Black Americans with CKD.

Authors:  Shengyuan Luo; Josef Coresh; Adrienne Tin; Casey M Rebholz; Teresa K Chen; Salim S Hayek; Melissa Tracy; Michael S Lipkowitz; Lawrence J Appel; Andrew S Levey; Lesley A Inker; Jochen Reiser; Morgan Erika Grams
Journal:  Clin J Am Soc Nephrol       Date:  2018-06-14       Impact factor: 8.237

8.  Vascular Structure and Inflammation in a South African Population: The SABPA Study.

Authors:  Carla Swart; Leandi Lammertyn; Paul I Welsh; Shani Botha-Le Roux
Journal:  Pulse (Basel)       Date:  2019-07-10

Review 9.  The glomerular filtration barrier: a structural target for novel kidney therapies.

Authors:  Ilse S Daehn; Jeremy S Duffield
Journal:  Nat Rev Drug Discov       Date:  2021-07-14       Impact factor: 84.694

10.  Linking stressful life events and chronic inflammation using suPAR (soluble urokinase plasminogen activator receptor).

Authors:  Kyle J Bourassa; Line J H Rasmussen; Andrea Danese; Jesper Eugen-Olsen; HonaLee Harrington; Renate Houts; Richie Poulton; Sandhya Ramrakha; Karen Sugden; Ben Williams; Terrie E Moffitt; Avshalom Caspi
Journal:  Brain Behav Immun       Date:  2021-07-02       Impact factor: 19.227

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.